Cullinan Therapeutics reports 39% objective response rate for zipalertinib in NSCLC patients with EGFR Exon 20 mutations in Phase 2b REZILIENT1 study.
Cullinan Therapeutics announces positive initial data from its Phase 2b REZILIENT1 study, showing zipalertinib had an objective response rate of 39% with a manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations. The study included 31 enrolled patients who had received a median of three prior systemic anti-cancer regimens.
June 01, 2024
4 Articles